Word count (abstract): 11 Word count (main text): 12 2 Abstract (250 words) 13 The PML (promyelocytic leukemia) protein is a member of the TRIM family, a large group of 14 proteins that show high diversity in functions but possess a common tripartite motif giving the 15 family its name. We and others recently reported that both murine and human PML strongly 16 restrict the early stages of infection by HIV-1 and other lentiviruses when expressed in mouse 17 embryonic fibroblasts (MEFs). This restriction activity was found to contribute to the type I 18 interferon (IFN-I)-mediated inhibition of HIV-1 in MEFs. Additionally, PML caused 19 transcriptional repression of the HIV-1 promoter in MEFs. By contrast, the modulation of the 20 early stages of HIV-1 infection of human cells by PML has been investigated by RNAi with 21 unclear results. In order to conclusively determine whether PML restricts HIV-1 or not in human 22
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making it possible to analyze whether PML modulates the restriction of retroviruses by this well-134 characterized restriction factor. Infectivity of the three lentiviral vectors (HIV-1, SIVmac, EIAV) 135 was slightly higher in the absence of PML at most virus doses used, whereas infectivity of the B-136 MLV vector was unaffected by PML knockout (Fig. 2C) . These results suggest that PML has a 137 small, barely detectable inhibitory effect on the infection of THP-1 cells by lentiviruses and does 138 not modulate TRIM5α activity. Treatment with IFN-β strongly decreased THP-1 permissiveness 139 to all four vectors, preventing us from measuring the -fold decrease in infectivity with accuracy 140 (Fig. 2C ). However, it was clear that IFN-β efficiently inhibited infection in the presence or 141 absence of PML, indicating that PML is not crucial for the IFN-I-mediated anti-retroviral 142 response.
143
Knocking out PML in human epithelial cells has little to no effect on the permissiveness to 144 retroviral infections in the presence or absence of IFN-I. We then transduced epithelial 145 carcinoma HeLa cells with the the CAG or PML gRNAs. PML was efficiently knocked out, as 146 seen by WB (Fig. 3A) . We also performed immunofluorescence microscopy to analyze the effect 147 of PML knockout on PML and SUMO nuclear bodies. A large part (but not all) of localizes to PML bodies in normal conditions (40) . As expected, signal corresponding to PML 149 nuclear bodies almost completely disappeared from the cells transduced with the PML gRNA 150 (Fig. S1 ). In addition, SUMO-1 punctate nuclear staining was strongly diminished but not 151 abolished ( Fig. S1 ). We then challenged the stably transduced cells with GFP-expressing viral 152 vectors like we had done in THP-1 cells. We found that susceptibility to SIVmac, EIAV 153 and B-MLV vectors was identical whether PML was present or not ( Fig. 3B-C) . all four viral vectors, although the magnitude of this effect (~2-to 3-fold) was much smaller than 155 in THP-1 cells. IFN-β treatments had identical effects in PML-expressing and PML-knockout 156 cells, again showing that PML does not modulate this inhibitory pathway in human cells. 157 Rhabdomyosarcoma-derived epithelial TE671 cells were similarly knocked out for PML by 158 lentiviral transduction, and knockout was efficient (Fig. 4A) . Similar to what we found in HeLa 159 cells, infectivity of the four vectors tested was identical whether PML was present or not (Fig. 160 4B). IFN-β decreased the permissiveness of TE671 cells to all four vectors, although we noticed 161 that IFN-β had a relatively smaller effect on HIV-1 NL-GFP compared with the three other vectors 162 in TE671 (Fig. 4B ). The IFN-β-induced inhibition of the four retroviral vectors in TE671 cells 163 was identical whether PML was present or not ( Fig. 4B ).
164
A knock-in approach to suppress PML in human cells. In order to achieve efficient knockout 165 by transient transfection without the need to isolate cellular clones by limiting dilution, we 166 constructed a plasmid to serve as donor DNA in homology-directed repair (HDR). This plasmid 167 contains two ~800bp-long PML homology arms surrounding a neomycin resistance cassette (Fig. 168 5A). It is expected that its co-transfection in cells along with Cas9 and the hPML gRNA1 would 169 lead to the knock-in of Neo R in PML through HDR in a fraction of the cells. Selection in 170 neomycin then eliminates cells in which the knock-in did not occur. Even if not all alleles of a 171 given gene are successfully modified by knock-in, recent reports indicate that the remaining ones 172 are usually knocked out through NHEJ-dependent mechanisms (41). We designed PCR primers 173 for the specific amplification of the knock-in product and another pair to amplify the wild-type 174 (WT) or the NHEJ-repair knockout alleles ( Fig. 5A ). To validate this system, we co-transfected 175 TE671 cells with pLCv2.PML1 and the HDR donor plasmid, and randomly isolated a number of 176 neomycin-resistant cell clones of which a representative analysis is shown in Fig. 5B . The 177 knock-in product was detected as expected in all 7 clones while being absent in the parental 178 cells. On the other hand, the band corresponding to WT or NHEJ-repaired alleles was less 179 intense in these clones relative to the parental cells, but was always present, suggesting that 180 HDR-mediated knockout did not affect all the PML alleles.
181
PML is important for the efficient inhibition of SIVmac but not HIV-1 by IFN-I in 182 lymphoid cells. We knocked out PML in Jurkat cells using the transfection approach that results 183 in the insertion of Neo R in PML, as described above. We performed WB analyses to assess in these cells, we also analyzed the effects of IFN-α and IFN-ω. (Fig. 6C ). We found that in PML isoforms that would normally not be apparent due to the presence of other isoforms. We 213 retrovirally transduced the isoforms I to VI of hPML into PML-KO Jurkat cells, separately.
214
Because HIV-1 is inhibited by mPML in MEFs (32-34), we also transduced mPML. A WB 215 analysis showed that all six isoforms of hPML were expressed, as was mPML isoform 2 (Fig. 216 7A). We then challenged the various cell cultures with the HIV-1, SIVmac, EIAV and B-MLV 217 vectors ( Fig. 7B ). We found that none of the PML isoforms had an effect on GFP transduction 218 by HIV-1 NL-GFP . Interestingly, several hPML isoforms and mPML slightly increased 219 permissiveness to SIV mac-GFP , by ~2-fold. Permissiveness to EIAV GFP was significantly decreased 220 by over-expression of hPML-IV, hPML-VI and mPML. Finally, the presence of hPML-VI also 
228
The possibility of PML involvement in the inhibition of retroviruses by TRIM5α has been 229 envisioned but not proven. The infectivity of the EIAV vector used here (which is restricted 5-to 230 10-fold by human TRIM5α (44)) was not significantly affected by knocking out PML ( Fig. 2-4) , 231 suggesting that TRIM5α does not require PML. In order to increase sensitivity, we used an "N-232 tropic" strain of MLV, which is even more strongly restricted by human TRIM5α (39, 45) than 233 EIAV, and of which restriction is counteracted by As 2 O 3 in a cell context-specific fashion (46, 234 47). Thus, As 2 O 3 greatly increases the infectivity of N-MLV but not B-MLV vectors in many 235 human cell lines. The mechanism of action of As 2 O 3 against TRIM5α has not been determined 236 but it was thought to involve PML, since As 2 O 3 is well-known as a specific inhibitor of PML 237 (27, 48). Interestingly, As 2 O 3 also enhances the infectivity of HIV-1 in human cells, although the 238 magnitude of this effect is milder than what is found with N-MLV (46, 49). We infected HeLa, 239 TE671 and Jurkat cells with HIV-1 NL-GFP , B-MLV GFP and N-MLV GFP in the presence of 240 increasing As 2 O 3 concentrations (Fig. 8A ). In the absence of As 2 O 3 , N-MLV GFP infectivity was 241 barely detectable or undetectable in all three cell lines, reflecting the strong inhibition conferred 242 by TRIM5α in human cells. At the same virus dose, B-MLV GFP infected 3% to 5% of the cells.
243
PML knockout had no effect on the infectivity of the two MLV vectors, implying that PML is 244 not required for TRIM5α-mediated restriction of N-MLV. In presence of As 2 O 3 , N-MLV GFP 245 infectivity was greatly enhanced, although the stimulating effect was partly reversed at high 246 As 2 O 3 concentrations in HeLa and TE671 cells ( Fig. 8A ). As 2 O 3 effectiveness at counteracting 247 TRIM5α-mediated restrictions was found to decrease at high concentrations in previous studies 248 as well (47, 49) . In contrast to N-MLV GFP , B-MLV GFP was only slightly enhanced by As 2 O 3 . As 249 reported before, As 2 O 3 modestly increased HIV-1 NL-GFP infection of HeLa and TE671 cells, 250 although it had no effect on this vector in Jurkat cells (Fig. 8B ). Knocking out PML had no exposure of the cells to HIV-1 did not modify this pattern (Fig. 9A) . The cells were then 272 challenged with HIV-1 NL-GFP or with the relatively restriction insensitive SIV mac-GFP as a control 273 (52). HIV-1 was very strongly restricted by rhTRIM5α in both WT and PML-KO MEF cells 274 (Fig. 9B ). As expected, C35A rhTRIM5α and hTRIM5α (WT or C35A) had little to no effect on 275 HIV-1 NL-GFP . SIV mac-GFP was moderately restricted by rhTRIM5α, and PML knockout did not 276 affect this inhibitory effect (in fact, restriction was slightly greater in the absence of PML) ( Fig.   277 9B). In conclusion, PML is not required for rhTRIM5α to restrict HIV-1. in recent years, as it was proposed to act as an HIV-1 restriction factor in mouse and human cells 289 (33). However, the data gathered so far by three different teams, including this study, suggest 290 that the restriction activity in human cells, if it exists, is cell type-specific. Dutrieux and 291 colleagues, using shRNAs, observed a modest inhibition of HIV-1 vector transduction conferred 292 by PML in HeLa cells (<2-fold). They also observed a small delay in HIV-1 propagation in 293 peripheral blood mononuclear cells, but the decrease in infectivity was not quantified (33). We 294 previously observed that knocking down PML in T-lymphoid Sup-T1 cells increases HIV-1 295 infectivity by 2-to 4-fold (34). On the other hand, Kahle and colleagues saw no effect of 296 knocking down PML on the infectivity of an HIV-1 vector in T lymphoid cell lines including 297 CEM, HuT78, Jurkat and Molt4 (32). They showed, however, that PML reduces HIV-1 298 infectivity in human foreskin fibroblasts by 2-to 3-fold (32). Taken together, those previous 299 papers showed that knocking down PML has either no effect or modest effects on HIV-1 300 infectivity in human cells. We were not able to efficiently knock out PML in Sup-T1 cells, Thus, it is possible that this hPML isoform contributes to the inhibition of specific retroviruses in 308 this cell line. However, the effects seen are probably too small for us to characterize a 309 mechanism or identify determinants of the restriction.
310
A recent study by Kim and Ahn (38) uncovered an additional function for PML in human skin 311 fibroblasts: the stimulation of ISG expression through a direct association with their promoter.
312
Accordingly, we previously showed that PML was important for the efficient inhibition of HIV-1 313 by IFN-I in MEF cells (34). Although HIV-1 is also readily inhibited by IFN-I in a variety of 314 human cell types, as illustrated in our study, we find that this effect is not affected by knocking 315 out PML. However, we cannot exclude the possibility that PML is involved in regulating IFN-I-316 dependent transcription in specific cellular contexts such as skin fibroblasts (38). It is also 317 possible that PML stimulates the transcription of some ISGs but not others. In support of this 318 idea is our observation that SIVmac inhibition by IFN-I in Jurkat cells was significantly greater 319 in the presence of PML. SIVmac, but not HIV-1, is inhibited by an unidentified restriction factor 320 in Jurkat cells and other T cells, provisionally called Lv4 (55). It is conceivable that the gene 321 encoding Lv4 is specifically stimulated by IFN-I in a PML-dependent fashion in Jurkat cells.
322
This characteristic could be exploited to identify this gene, similar to the strategy that led to the 323 identification of Tetherin as a retroviral restriction factor (56).
324
In our previous study (34), we showed that PML inhibited HIV-1 transcription in MEFs but not 325 in Sup-T1 cells and in an IFN-I-independent fashion. We analyzed GFP mean fluorescence 326 intensity in all our experiments for this study, as a surrogate for HIV-1 gene expression levels.
327
Consistent with our previous findings, we observed no effect of PML on the GFP fluorescence 328 intensity following infection of THP-1, Jurkat, HeLa or TE671 cells with our various vectors 329 (not shown). We conclude that PML does not repress HIV-1 transcription in human cells. This 330 apparently contradicts a report by Giacca and colleagues that PML inhibits HIV-1 transcription 331 by directly binding the viral promoter (31). However, the latter study was based on the use of "J-
332
Lat" clones, which are Jurkat cells in which the HIV-1 provirus has become constitutively 333 repressed through unknown mechanisms (57). We propose that PML may be involved in the rare 334 silencing events leading to HIV-1 latency in Jurkat cells, and that PML is important for the 335 maintenance of silencing; however, PML is not a ubiquitous silencer of HIV-1 transcription.
336
Finally, our study shows that the As 2 O 3 -mediated stimulation of early retroviral infection stages 337 is completely independent of PML, and so is the inhibition of TRIM5α by this drug. This is not 338 entirely surprising, considering that TRIM5α can target N-MLV in human cells, and HIV-1 in 339 MEF cells, in the absence of PML. However, these results challenge conclusions from another 340 paper that used radioactively or chemically labelled arsenate compounds to show that PML was 341 the main target for this group of pharmacological agents (27) 
356

Plasmids and preparation of retroviral vectors 357
The pMIP retroviral vector plasmids containing individual isoforms of hPML (pMIP-hPML-I to 358 VI) and the isoform 2 of mPML (pMIP-mPML) have been described in details in a recent 359 publication (34) and make use of materials generously provided by Roger D. Everett (60) .
360
Retroviral vectors were prepared by co-transfection of 293T cells with pMIP-m(h)PMLs together 361 with pMD-G and pCL-Eco using polyethylenimine (PEI; Polyscience, Niles, IL) as detailed 362 previously (34). Virus-containing supernatants were collected 2 d later, clarified by low-speed 363 centrifugation and kept at -80 o C.
364
To produce GFP-expressing retroviral vectors, 293T cells were seeded in 10 cm culture dishes 365 and transiently co-transfected with the following plasmids: pMD-G, pCNCG and pCIG3-B or 366 pCIG3-N to produce B-MLV GFP and N-MLV GFP , respectively; pMD-G and pHIV-1 NL-GFP to 367 produce HIV-1 NL-GFP ; pMD-G and pSIV mac239-GFP to produce SIV mac-GFP ; or pONY3.1, pONY8.0 368 and pMD-G to produce EIAV GFP (see (34, 61) and references therein).
369
Design of gRNAs and transduction of lentiviral CRISPR-Cas9 vectors 370
The lentiviral expression vector plentiCRISPRv2 (pLCv2) was a gift from Feng Zhang (Addgene 371 plasmid # 52961) and can be used to simultaneously express a gRNA, Cas9 nuclease, and 372 puromycin resistance, either by transfection or lentiviral transduction (62). Two gRNAs (hPML1 373 and hPML2) targeting hPML (NG_029036) were designed using the Zhang lab online software 374 available at crispr.mit.edu. The sequences targeted are 5'CAATCTGCCGGTACACCGAC 375 (hPML1) and 5'CACCGGGAACTCCTCCTCCGAAGCG (hPML2). A gRNA targeting the 376 CAG hybrid promoter (target: 5'GTTCCGCGTTACATAACTTA) was used as a negative 377 control (35). The oligodeoxynucleotides (ODNs) needed for the generation of pLCv2-based 378 constructs were designed according to the Zhang lab protocol (62, 63) and are shown in Table   379 S1.
380
The lentiviral vectors were prepared by co-transfection of 293T cells with 10 µg of the 381 plentiCRISPRv2 construct together with 5 µg of pMD-G and 10 µg of pΔR8.9 (64). The viral 382 supernatants were collected at 1.5 or 2 d post-transfection and used to transduce various cell 383 lines. Stably transduced cells were selected by addition of 0.5 µg/ml puromycin (Thermo Fisher 384 Scientific) to the medium at 2 d post-infection and for 5 d. Control untransduced cells were 385 killed under these conditions.
386
Surveyor nuclease assay 387 To evaluate on-target modifications (indels) in hPML, a surveyor nuclease assay was performed.
388
293T cells were transfected with either plentiCRISPRv2-hPML1, -hPML2 or -CAG using PEI. 3 389 d later, the genomic DNA was extracted from the transfected cells using the QIAamp DNA mini 390 kit (Qiagen, CA, USA). Two pairs of primers were designed to amplify 637 bp and 725 bp 391 fragments on either side of Cas9 targets guided by gPML1 and gPML2 respectively (Fig. 1A) .
392
The sequences of these ODNs are included in Table S1 . PCR amplicons were heat-denatured at 393 95 °C, and re-annealed by slow cooling to promote formation of dsDNA heteroduplexes. The 
Construction of the homology directed repair (HDR) plasmid and generation of PML-KO
398
Jurkat cells 399 We used pcDNA3.1+ as the backbone plasmid to prepare a HDR "donor" plasmid containing a 400 neomycin selection gene (Neo R ). First, the backbone plasmid was cut with BamHI and BglII, 401 then self-ligated in order to remove the cytomegalovirus promoter from upstream of the 402 multicloning site MCS1. Next, two ODNs were designed to introduce the second MCS (MCS2) 403 (see Table S1 ); these ODNs were annealed, and the resulting duplex ligated into the PciI cut site 
428
Pharmacological treatments. A 0.1 M stock solution of As 2 O 3 (Sigma) was prepared in 1 N 429 NaOH, as previously described (28), and diluted in the culture medium immediately before use. 
